What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-03-25 compared with 2023-03-14 · 25 added, 19 removed, 8 unchanged (85% of the section changed)

1 unchanged sentence

for Common Equity

common stock is traded on the Nasdaq Global Market under the symbol “LUCD”.

As of March 9, 2023, there were 43,393,716 shares of our common stock

Our shares of common stock are held by an estimated 19 holders of record and we believe our shares of common stock are held

by significantly more beneficial owners.

common stock is traded on the Nasdaq Capital Market under the symbol “LUCD”.

of March 21, 2024, there were 48,244,798 shares of our common stock issued.

Our shares of common stock are held by an estimated

256 holders of record and we believe our shares of common stock are held by significantly more beneficial owners.

have not paid any cash dividends on our common stock to date.

1 unchanged sentence

We do not anticipate paying dividends in the foreseeable future but expect to retain earnings to finance the growth of our business.

Our board of directors has complete discretion on whether to pay dividends.

Even if our board of directors decides to pay dividends,

the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial

condition, contractual restrictions and other factors the board of directors may deem relevant.

Subject to the restrictions described below and applicable law, our board of directors has complete discretion on whether to pay dividends.

Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings,

capital requirements and surplus, general financial condition, contractual restrictions, amongst and other factors deemed relevant.

long as the Senior Convertible Note (see “ Liquidity and Capital Resources ” in Item 7 below) is outstanding, we may

not, directly or indirectly, redeem, or declare or pay any cash dividend or cash distribution on, any of our securities without the prior

express written consent of the purchasers of the Senior Convertible Note.

Furthermore, our common stock is junior to our preferred stock

with respect to certain in-kind dividends payable to the holders of such preferred stock.

B Preferred Stock

The holders of Series B

Preferred Stock are entitled to dividends payable as follows:

(i) a number of shares of common stock equal to 20% of the number of

shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on March 13, 2025, and (ii)

a number of shares of common stock equal to 20% of the number of shares of common stock issuable upon conversion of the Series B

Preferred Stock then held by such holder on March 13, 2026.

Under the terms of the Series B Preferred Stock, a holder that converts

its Series B Preferred Stock prior to March 13, 2025 or March 13, 2026, as the case may be, will not receive the dividend that

accrues on such date with respect to such converted Series B Preferred Stock.

The holders of the Series B Preferred Stock also will

be entitled to dividends equal, on an as-if-converted to shares of common stock basis, to and in the same form as dividends actually

paid on shares of the common stock when, as, and if such dividends are paid on shares of the common stock.

Sales of Unregistered Securities and Use of Proceeds

1 unchanged sentence

not sell any unregistered securities or repurchase any of our securities during the fiscal year ended December 31, 2023.

October 14, 2021, we completed our initial public offering (“IPO”) of our common stock under an effective registration statement

on Form S-1 (SEC File No.

As of December 31, 2022, of the net proceeds of $64.4 million, approximately $43.7 million has

been used, in a manner consistent with the use of proceeds set forth in the prospectus for our IPO, as follows:

approximately $5.3 million

of net repayments of Due To:

approximately $5.0 million for the purchase of our laboratory equipment, software, and its

operating expenses;

and $33.4 million of working capital expenditures.

None of the proceeds have been paid to any of our directors, officers,

10% stockholders, or affiliates, other than as described above.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity